This finding is in line with several studies where therapeutics exert their anti-cancer activity in general and in AML in particular, through restoring p53 activity and downregulating HDM2 expression [55,56,57,58,59,60,61]. This evidence concerns the gene TP53 and acute myeloid leukemia.